Big Pharma Headcounts: Obesity Leaders Bulk Up As Others Go Lean

As Eli Lilly and Novo Nordisk reap the blockbuster rewards of their rival obesity therapies the companies are also bulking up their organizations to make the most of the phenomenal rise of the GLP-1 class.

More from Outlook

More from Leadership